Kang, Mi-jung
(Dept. of Oriental Internal Medicine, Dong-Seo Oriental Medicine Hospital)
Lee, Dong-keun (Dept. of Oriental Internal Medicine, Dong-Seo Oriental Medicine Hospital) Son, Ah-hyun (Dept. of Oriental Internal Medicine, Dong-Seo Oriental Medicine Hospital) Shin, Hyeon-su (Dept. of Oriental Internal Medicine, Dong-Seo Oriental Medicine Hospital) |
1 | Kwack JJ, Lee YS, Choi CW, Lee GN, Kim HC. A Case of Chronic Myeloblastic Leukemua with Intracerebral Hemorrhage. Korean J Orient Int Med 2002;23(2):260-7. |
2 | Lee JL, Ha KS, Song IS, Shin JN. The Clinical Study on a Case of Acute Myelogenous Leukemia. J Korean Orient Pediatr 2004;18(2):49-59. |
3 | Yoon SW, Park JW, Kim KS, Jung HS, Choi WC. The Study on the Safety and Case Series of the Acute Lymphocytic Leukemia using Rhus Verniciflua Stokes Extract (Nexia). J Korean Tradit Oncol 2006;11(1):1-21. |
4 | Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61. DOI |
5 | Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12(9):841-51. DOI |
6 | Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009;115(7):1381-94. DOI |
7 | Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118(17):4567-76. DOI |
8 | Conchon M, Freitas CM, Rego MA, Braga Junior JW. Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia. Rev Bras Hematol Hemoter 2011;33(2):131-9. |
9 | Sprycel - FDA prescribing information, side effects and uses. http://www.drugs.com/pro/sprycel.html |
10 | Masiello D, Gorospe G Ⅲ, Yang AS. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol 2009;2:46. DOI |
11 | Yoon YG. Donguibangjewa chuhbanghaeseol. Seoul: Euiseongdang; 1998, p. 219. |
12 | Jeong JY, Ahn SY, Cho DH, Doo HK, Yang MH. The Effects of Paeryungsan and Bojungchiseubtang on Rats with Nephrosis Induced by Puromycin Aminonucleoside. Kyung-Hee Oriental Medical Dissertations Collection 1995;18(2):59-79. |
13 | Oh JK, Lee MJ. The Effects of Bo-Jung-Chi-Seub-Tang Administration on Body Composition, Blood Biochemistrical Factors and Hormonal Changes during 2 weeks Weight Reduction in TaeKwonDo Athletes. J Korean Med 1998;19(2):391-400. |
14 | Kim JG, Kim YG, Ryoo JH, Lee HS. Effects of Bojungchiseuptang on the Renal Function in Rats. J Physiol & Pathol Korean Med 2001;15(2):296-9. |
15 | Kang DG, Kim JG, Kim BH, Cho DK, Sohn EJ, Ryu DG, et al. Effects of Bojungchiseup-tang on Renal Expression of Water Channels, Na, K-ATPase and Nitric Oxide Synthase in Rats. J Physiol & Pathol Korean Med 2002;16(1):72-7. |
16 | Choi SH. Donguijongyanghak. Seoul: Haengrim publisher; 1995, p. 245-6. |
17 | Kim DY, Lee JO, Kim KH, Kim BS, Kim SH, Kim YK, et al. Korean Guidelines for Treating Chronic Myelogenous Leukemia - The Korean Society of Hematology Chronic Myelogenous Leukemia Working Party. Korean J Med 2015;88(4):406-19. DOI |
18 | Kim DH, Goh HG, Kim SH, Choi SY, Park SH, Jang EJ, et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol 2012;96(1):47-57. DOI |
19 | Kim DW. Recent Advances of Management for Chronic Myeloid Leukemia. Korean J Med 2012;83(6):718-23. DOI |
20 | Baik TH, Ryu KW. One Case of Chronic Myelogenous Leukemia Treatment (By Gamisiryungtang hab bopaewontang and Gamibopaewontang). J Korean Med 1989;10(2):86-9. |